Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced nonsmall cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone

被引：0
|
作者：
Bureau, M. [1 ]
Chatelier, T. [2 ]
Perennec, T. [1 ]
Goronflot, T. [3 ]
Greilsamer, C. [4 ]
Chene, A-L. [5 ]
Affi, R. [1 ]
Bennouna, J. [1 ]
Pons-Tostivint, E. [1 ]
机构：
[1] Univ Hosp Nantes, Dept Pneumol, Thorac Med Oncol Funct Unit, Nantes, France
[2] Clin Mutualiste Estuaire, Med Oncol, St Nazaire, France
[3] Univ Hosp Nantes, Biostat Dept, Nantes, France
[4] Hosp La Roche Sur Yon, Med Oncol, La Roche Sur Yon, France
[5] Univ Hosp Nantes, Pneumol Dept, Nantes, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1295P
引用
收藏
页码：S1004 / S1004
页数：1
相关论文
共 50 条
  • [1] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Bureau, Mathilde
    Chatellier, Thierry
    Perennec, Tanguy
    Goronflot, Thomas
    Greilsamer, Charlotte
    Chene, Anne-Laure
    Affi, Raafet
    Frampas, Eric
    Bennouna, Jaafar
    Pons-Tostivint, Elvire
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756
  • [2] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Mathilde Bureau
    Thierry Chatellier
    Tanguy Perennec
    Thomas Goronflot
    Charlotte Greilsamer
    Anne-Laure Chene
    Raafet Affi
    Eric Frampas
    Jaafar Bennouna
    Elvire Pons-Tostivint
    Cancer Immunology, Immunotherapy, 2022, 71 : 1747 - 1756
  • [3] Advanced non-small cell lung cancer with PD-L1≥50%: Pembrolizumab alone or combined with chemotherapy
    Han, B.
    Han, B.
    Zhang, B.
    Hu, M.
    Wang, Y.
    Yang, Z.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S759
  • [4] Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
    Llop Serna, S.
    Puig, E.
    Palmero, R.
    Brenes, J.
    Vilarino, N.
    Ruffinelli, J. C. C.
    Mesia Barroso, C.
    Saldana Canada, J.
    Jove Casulleras, M.
    Brao Perez, I.
    Arellano, M.
    Luciano Mateo, F. N.
    Peiro Martinez, I.
    Munoz Pinedo, C.
    Nadal, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1012 - S1012
  • [5] Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts)
    Tay, R. Y.
    Chiramel, J.
    Montague, E.
    Wilson, F.
    Summers, Y.
    Blackhall, F. H.
    Califano, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 529 - 529
  • [6] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
    Doubre, Helene
    Greillier, Laurent
    Justeau, Gregoire
    Ricordel, Charles
    Swalduz, Aurelie
    Curcio, Hubert
    Bylicki, Olivier
    Auliac, Jean-Bernard
    Guisier, Florian
    Bigay-Game, Laurence
    Bernardi, Marie
    Pinsolle, Julian
    Amrane, Karim
    Decroisette, Chantal
    Descourt, Renaud
    Chouaid, Christos
    Geier, Margaux
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15095 - 15102
  • [7] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
    Hélène Doubre
    Laurent Greillier
    Grégoire Justeau
    Charles Ricordel
    Aurélie Swalduz
    Hubert Curcio
    Olivier Bylicki
    Jean-Bernard Auliac
    Florian Guisier
    Laurence Bigay-Game
    Marie Bernardi
    Julian Pinsolle
    Karim Amrane
    Chantal Decroisette
    Renaud Descourt
    Christos Chouaid
    Margaux Geier
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15095 - 15102
  • [8] Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes
    Franco, A. Ortega
    Tay, R.
    Raja, H.
    Ackermann, C. J.
    Carter, M.
    Lindsay, C.
    Hughes, S.
    Cove-Smith, L.
    Taylor, P.
    Summers, Y.
    Blackhall, F. H.
    Califano, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S284 - S284
  • [9] Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice
    Ksienski, D.
    Wai, E.
    Croteau, N.
    Freeman, A.
    Fiorino, L.
    Chan, A.
    Fenton, D.
    Geller, G.
    Brooks, E.
    Poonja, Z.
    Irons, S.
    Lesperance, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S276 - S277
  • [10] PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade
    Yoshida, Hironori
    Nomizo, Takashi
    Ozasa, Hiroaki
    Tsuji, Takahiro
    Funazo, Tomoko
    Yasuda, Yuto
    Ajimizu, Hitomi
    Yamazoe, Masatoshi
    Kuninaga, Kiyomitsu
    Ogimoto, Tatsuya
    Hosoya, Kazutaka
    Itotani, Ryo
    Sakamori, Yuichi
    Kim, Young Hak
    Hirai, Toyohiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 317 - 325
12345